Walking offers a multitude of benefits. It reduces the risk of heart disease, diabetes, dementia, depression, cancer—you name it. However, at least 30 percent of people over 65 have difficulty walking three blocks or climbing one flight of stairs. As people…
Moderate-to-vigorous walking or other types of physical activity may improve retinal health, according to a large population study using a national database from the United Kingdom. The study included data from 11,165 adults in the UK Biobank who had had an…
A new phase 3 trial found that the antibody-drug conjugate risvutatug rezetecan (ris-rez) more than tripled the median progression-free survival (PFS) compared with chemotherapy in patients with relapsed or refractory osteosarcoma. In the randomized Artemis-011 trial involving 122 patients, median PFS was…
The resistance of doxorubicin (DOX), the first-line chemotherapeutic drug for osteosarcoma (OS), stands as a pivotal obstacle in the effective treatment of OS. Alterations in mitochondrial dynamics and thereby affecting reactive oxygen species (ROS)... Uncover the latest and most impactful…
It's a question that surgeons often face: How much surrounding healthy tissue should they take out when removing a patient's cancer to be sure it is fully eliminated? Removing more can sacrifice nearby nerves, blood vessels, tendons and even joints,…
CBS News Texas is a local news organization that is part of CBS News and Stations. Also referred to as KTVT and channel 11, CBS News Texas offers local breaking news, weather coverage and investigative reporting. North Texas teen survives brain…
A community came together Sunday to support a 2-year-old girl and her family as she continues treatment for a rare form of liver cancer. MADRID, Oct 28 (Reuters) - Two high-speed trains have collided in Spain, prompting the suspension of the line…
The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen. Most patients are diagnosed with mesothelioma late, resulting in a median overall survival of just…
Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011. Per blinded independent central review (BICR), the median PFS was 5.5 months (95% CI, 4.1-7.4) with ris-rez vs 1.4 months (95% CI, 0.8-2.7) with gemcitabine…
Median PFS assessed by blinded independent central review (BICR) was 5.5 months for patients randomized to receive Ris-Rez compared with 1.4 months for those who received gemcitabine and docetaxel (HR 0.33, 95% CI 0.20-0.55, P The PFS rate at 4 months was 65% with the B7-H3-targeted drug…
Sarcomas of bone and soft tissue, neuroendocrine tumours, mesothelioma and other rare cancers.
An article joins this feed when it matches these terms. Each one is also a search of its own.